2016
DOI: 10.1016/j.ijpsycho.2016.01.006
|View full text |Cite
|
Sign up to set email alerts
|

Modeling cyclic variations in sustained human performance as measured by reaction time and the flash visual evoked potential-P2

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 27 publications
0
1
0
Order By: Relevance
“…In a recent review of the flash visual evoked potential P2 (FVEP-P2) literature, Arruda and colleagues 1 examined the diagnostic accuracy of the FVEP-P2 when used as a biomarker for amnestic mild cognitive impairment (aMCI) and Alzheimer's dementia (AD). The results of that review, which included the data from 17 empirical investigations, suggested that the FVEP-P2 latency, an index of visual cholinergic functioning 26 may contain pathognomonic information that the more sophisticated approaches of diagnosing aMCI and AD, including cerebral spinal fluid (CSF) and brain imaging (eg, positron emissions tomography, PET) 710 may not. It was also noted in the review 1 that unlike today's leading approaches in the detection of AD (ie, CSF-tau and FDG-PET) 7,9 the FVEP-P2 biomarker does not assume the amyloid hypothesis to be true and, therefore, has not been restricted in its approach to the early detection of aMCI and AD.…”
Section: Introductionmentioning
confidence: 99%
“…In a recent review of the flash visual evoked potential P2 (FVEP-P2) literature, Arruda and colleagues 1 examined the diagnostic accuracy of the FVEP-P2 when used as a biomarker for amnestic mild cognitive impairment (aMCI) and Alzheimer's dementia (AD). The results of that review, which included the data from 17 empirical investigations, suggested that the FVEP-P2 latency, an index of visual cholinergic functioning 26 may contain pathognomonic information that the more sophisticated approaches of diagnosing aMCI and AD, including cerebral spinal fluid (CSF) and brain imaging (eg, positron emissions tomography, PET) 710 may not. It was also noted in the review 1 that unlike today's leading approaches in the detection of AD (ie, CSF-tau and FDG-PET) 7,9 the FVEP-P2 biomarker does not assume the amyloid hypothesis to be true and, therefore, has not been restricted in its approach to the early detection of aMCI and AD.…”
Section: Introductionmentioning
confidence: 99%